{"product_id":"11r-vivit-tfa-p1210","title":"11R-VIVIT TFA","description":"\u003ch2\u003eAbout the Target\u003c\/h2\u003e\u003cp\u003e11R-VIVIT TFA (NFAT inhibitor), a short peptide, inhibits NFAT activation through interaction with the calcineurin binding site for NFAT and thus prevents nuclear translocation without affecting calcineurin phosphatase activity. The mapped biological anchor for this entry is NFAT-calcineurin signaling axis, although the description suggests that interpretation should remain at fragment, family, or pathway level. The mapped biology sits at the level of transcriptional control or regulated nuclear signaling, making the reagent useful when pathway activation needs to be connected to movement of signaling proteins and downstream gene-expression changes. Across mechanistic studies, investigators commonly track acute pathway activation, receptor trafficking, and downstream transcriptional changes. For experimental design, the entry is most relevant to studies that move from early pathway perturbation to later endpoint phenotypes.\u003c\/p\u003e\u003ch2\u003eResearch Context\u003c\/h2\u003e\u003cp\u003eIts value in research often comes from perturbing a defined protein-protein interaction, which can separate docking-dependent signaling from total target abundance. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses. The available sequence cue can also be useful for tracking construct identity across screening and follow-up experiments. Because the enrichment is not fully single-target, conclusions are usually strongest when they are framed around the intended biological process and confirmed with orthogonal markers.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003emeasure localization or pathway-proximal signaling together with endpoint gene-expression changes\u003c\/li\u003e\n\u003cli\u003euse time-course designs to distinguish rapid docking events from secondary transcriptional remodeling\u003c\/li\u003e\n\u003cli\u003ecompare phenotypes with rescue or pathway-orthogonal controls whenever practical\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eExperimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.\u003c\/p\u003e\u003ch2\u003eFormat Considerations\u003c\/h2\u003e\u003cp\u003eFor routine mechanistic work, the unmodified catalog format provides a consistent starting point for concentration-response studies, benchmark experiments, and orthogonal validation. In comparative workflows, keeping the listed tfa format constant across comparator groups can reduce avoidable formulation-related differences; documenting the provided sequence cue (11R-VIVIT) can support traceability in comparative studies. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.\u003c\/p\u003e","brand":"Selleck Chemicals","offers":[{"title":"5 mg","offer_id":57636813341017,"sku":"P1210-5MG","price":274.0,"currency_code":"EUR","in_stock":true},{"title":"25 mg","offer_id":57636813373785,"sku":"P1210-25MG","price":822.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0923\/1011\/0553\/files\/p1210-11r-vivit-tfa-chemical-structure.gif?v=1774212207","url":"https:\/\/absource-diagnostics.myshopify.com\/products\/11r-vivit-tfa-p1210","provider":"Absource Diagnostics","version":"1.0","type":"link"}